Moineauworld

Tag: safety

Lillys Retatrutide: Next Obesity | Analysis by Brian Moineau

Posted on by Brian Moineau

A new heavyweight enters the ring: retatrutide and Lilly’s obesity play

When Eli Lilly dropped the news that retatrutide — its next‑generation obesity drug — cleared a first late‑stage diabetes trial, the headlines didn’t just hum; they roared. Retatrutide is suddenly the conversation starter across clinics, investor decks, and patient forums because it promises to be the newest pillar in Lilly’s obesity portfolio alongside the injection Zepbound and the upcoming oral candidate, orforglipron. This isn’t incremental progress; it’s a strategic bet to widen Lilly’s lead in a market that keeps redefining itself.

What just happened

Lilly announced that a late‑stage study of retatrutide met its primary and key secondary endpoints, showing meaningful benefits for patients with obesity and related cardiometabolic conditions. That readout is the first of several late‑stage trials testing retatrutide across different indications — from obesity with osteoarthritis to type 2 diabetes — and it signals that the molecule is moving from promise toward potential approval and clinical use. (finance.yahoo.com)

Transitioning from trial results to market reality will take time, but this milestone is important: it validates the concept behind retatrutide as a “triple‑agonist” engineered to target multiple metabolic pathways, and it gives Lilly data to lean on as it positions the drug against both its own products and competitors.

Why retatrutide matters now

  • Lilly already has momentum. Zepbound (tirzepatide) shifted prescribing patterns and grabbed share from older GLP‑1 therapies. Adding retatrutide to that lineup could give clinicians and patients a stronger set of options for different needs and tolerances. (cnbc.com)
  • Orforglipron, Lilly’s oral GLP‑1 candidate, aims to broaden access for people who prefer pills over injections. Together, orforglipron, Zepbound and retatrutide form a diversified portfolio that addresses both convenience and efficacy. (cnbc.com)
  • The clinical data for retatrutide have shown unusually large weight‑loss signals in earlier studies, raising expectations that it could deliver more profound reductions than current standards. If sustained and safe in broader populations, that’s a game changer for severe obesity and its comorbidities. (finance.yahoo.com)

These factors help explain why investors, clinicians and competitors are watching closely: Lilly is stacking multiple approaches — injectable, oral, and a next‑gen triple agonist — all aimed at capturing distinct slices of a massive market.

Retatrutide in context of Lilly’s strategy

Lilly is deliberate here. Rather than relying on a single blockbuster, the company is building a suite of options:

  • Zepbound: a weekly injectable (tirzepatide) that already demonstrated strong weight‑loss outcomes and broad adoption.
  • Orforglipron: an oral GLP‑1 candidate targeting the convenience segment and potentially bringing more patients into treatment.
  • Retatrutide: a next‑generation, multi‑receptor agent designed to push efficacy higher for patients who need or want more substantial results.

That three‑pronged approach hedges commercial risk and addresses different patient preferences and clinical needs. It also positions Lilly to respond to pricing pressures and payer negotiations by offering differentiated products across efficacy and route‑of‑administration. Recent policy moves and pricing agreements in the U.S. (including government negotiations and payer covers) make having alternatives strategically valuable. (time.com)

The science: why a triple approach might be better

Retatrutide is engineered to act on multiple hormonal pathways involved in appetite, satiety and metabolism. The idea is simple: combine mechanisms to produce larger, sustained weight loss than single‑pathway drugs alone. Early results have been impressive in magnitude, but the real test is durability, safety, and performance across diverse, real‑world patients.

That’s why the ongoing late‑stage program — which spans obesity with comorbid conditions, type 2 diabetes, and organ‑specific indications like chronic kidney disease — matters. If retatrutide proves safe and effective across these studies, clinicians could gain a potent tool for patients with complex metabolic disease.

The competition and what’s at stake

Novo Nordisk remains a formidable competitor with Ozempic and Wegovy in the market and its own pipeline work. But Lilly’s aggressive pipeline and the breadth of indications it’s pursuing have shifted the competitive landscape. A broadly effective retatrutide would raise the bar on weight‑loss expectations — and force payers and clinicians to rethink treatment algorithms.

At the same time, the emergence of oral GLP‑1s (including other companies’ efforts) will change access dynamics. Pills are easier to distribute and may lower barriers for many patients. Lilly’s portfolio — injectable, pill, and next‑gen triple agonist — is designed to capture patients at multiple points along that adoption curve. (cnbc.com)

What to watch next

  • Upcoming readouts from the other TRIUMPH trials and indications, especially those focused on diabetes and organ‑specific outcomes.
  • Safety and tolerability data across larger and more diverse populations.
  • How payers respond: pricing, coverage decisions, and whether combinations of these drugs alter formularies.
  • Real‑world adoption patterns once orforglipron and (if approved) retatrutide become available.

Key points to remember

  • Retatrutide just cleared a meaningful late‑stage milestone, marking a significant step toward broader clinical use. (finance.yahoo.com)
  • Lilly is combining three product types — injection, pill, and a next‑gen triple agonist — to cover convenience and efficacy needs. (cnbc.com)
  • The stakes are high: safety, durability, access and payer decisions will determine whether retatrutide reshapes care or becomes another option among many.

My take

This is a pivotal moment for metabolic medicine. Retatrutide’s initial late‑stage win is the kind of data that shifts expectations, but the broader impact will depend on replicated results, safety, and how the market digests another powerful tool. Lilly’s multi‑product strategy is smart: it reduces single‑product risk and gives physicians flexibility. Still, success will require more than impressive trial numbers — it will require thoughtful rollout, accessible pricing, and clear guidance on where retatrutide fits in a crowded and evolving treatment landscape.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.

Inside the $160K Ammortal Recovery Chamber | Analysis by Brian Moineau

Posted on by Brian Moineau

Step inside the high-tech, futuristic-looking Ammortal chamber

I lay down, the lid curved like a spaceship overhead, and within seconds a warm red light flooded the cabin. Step inside the high-tech, futuristic-looking Ammortal chamber and you don’t just get light—you get a carefully choreographed stack of therapies: red and near‑infrared photobiomodulation, pulsed electromagnetic fields, vibroacoustics, guided breathwork, and even a sip of molecular hydrogen delivered by a tiny nasal tube. The first time I tried it, the room hummed, a steady vibration threaded through the mattress, and my whole body began to buzz in a way I hadn’t expected.

The Ammortal chamber (reported price around $159–160K) has been showing up in luxury spas, athletic recovery centers, and wellness suites. It’s designed to condense hours of separate modalities into one guided session—25 to 50 minutes of what its makers call “human optimization.” The experience feels cinematic: audio cues, dimming lights, tactile resonance, and a gentle voice that shepherds you through breathwork and relaxation.

Why the buzz? The science inside the Ammortal chamber

Several distinct technologies are layered in the chamber—and each has a research footprint of varying strength.

  • Photobiomodulation (red and near‑infrared light) is the centerpiece. Controlled exposure to these wavelengths can stimulate mitochondrial activity and has evidence supporting skin repair, reduced inflammation, and improved circulation.
  • Pulsed electromagnetic fields (PEMF) claim to influence cellular signaling and blood flow. Some studies suggest benefits for recovery and pain reduction, though results vary by protocol.
  • Vibroacoustics and synchronized sound can promote relaxation, modulate heart rate variability, and change perceived pain or stress.
  • Molecular hydrogen inhalation is offered as an antioxidant adjunct; preliminary studies hint at anti‑inflammatory effects but large clinical trials are limited.

Stacking these modalities may produce additive—or even synergistic—effects, but that’s also the trick: because multiple inputs happen at once it’s harder to isolate which element is doing the work. Expectation, environment, and the guided breathwork likely amplify outcomes via the nervous system’s top‑down influence.

What it actually feels like

The session begins with a mild mechanical hum. The red glow washes over your skin; vibrations travel through the bed; a voice asks you to breathe slowly. For many users the immediate sensation is a profound relaxation coupled with heightened sensation—the “buzz” people report. That buzzing can be physical (vibroacoustics + PEMF) and perceptual (your nervous system shifting from fight/flight toward parasympathetic calm).

Post‑session effects often described in reviews and first‑hand accounts include:

  • A sustained feeling of calm and mental clarity ("caffeinated calm").
  • Reduced muscle soreness or quicker perceived recovery.
  • Subtle changes in skin tone or texture after repeated use (attributed to red/NIR exposure).

These are promising but largely anecdotal outside carefully controlled studies. Still, for athletes and high‑performers willing to pay per session, the chamber’s immersive format is an attractive time‑saving convenience.

Who is the Ammortal chamber for?

  • Professional athletes and performance teams who value incremental recovery advantages.
  • Luxury spas and clinics that can amortize the hardware cost across many clients.
  • Biohackers and early adopters who prioritize novelty and are comfortable with premium pricing.

For most consumers, buying a full $160K unit is unrealistic. Fortunately, the model is showing up as per‑session offerings in select facilities, letting curious people test it without the full price tag.

The business and ethical angle

Ammortal’s price point places it firmly in high‑end wellness. The company has attracted investment from athlete backers and wellness entrepreneurs, and it’s exploring lower‑cost variants to broaden access. The flip side: a high price plus polished marketing can drive expectation biases. Wellness tech companies must be cautious not to overpromise while research continues to catch up.

There’s also a practical safety note: stacked therapies mean stacked risk considerations. Users with implanted electronic devices, certain medical conditions, or pregnancy should consult clinicians before trying electromagnetic or inhalation components.

A short list of practical questions before you try it

  • Do you have any implanted devices or medical conditions that could interact with PEMF or oxygen/hydrogen delivery?
  • Is the facility transparent about protocols, training, and emergency procedures?
  • Can you try a single session first to judge subjective effects before committing to a package?

Answering these will help reduce surprises and keep the experience restorative rather than unsettling.

The Ammortal chamber experience

I left feeling oddly energized and calm—an alertness without jitters. The buzzing faded over a few hours but a lighter, buoyant clarity stayed with me into the next day. That combination of restorative relaxation plus a perceptible “lift” is what many reviewers report: a short session that feels like pressed reset.

That said, a single immersion is unlikely to replace consistent sleep, nutrition, and movement. Think of the chamber as a high‑spec tool in the recovery toolbox: useful for targeted sessions, especially when paired with a broader lifestyle plan.

My take

The Ammortal chamber is striking because it packages multiple plausible wellness technologies into a single, polished experience. It’s equal parts engineering, psychology, and design. For people chasing marginal gains—athletes, celebrity clients, and affluent biohackers—the chamber offers a compelling, time‑efficient ritual. For everyone else, the novelty and reported benefits are interesting, but the science needs larger, controlled trials to parse what’s real, what’s synergistic, and what’s placebo.

If you get the chance to try one at a spa, bring curiosity and healthy skepticism. Lie down, breathe with the guide, and notice what shifts. The buzz might be the machine—or your body finally getting permission to relax. Either way, it’s futurescape wellness: roomy, red, and a little bit electric.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.

Related update: We recently published an article that expands on this topic: read the latest post.

Related update: We recently published an article that expands on this topic: read the latest post.

Related update: We recently published an article that expands on this topic: read the latest post.